VN February 2021

Vetnuus | Februarie 2021 4 Evidence-based medicine is defined by Sackett et al (BMJ, 1996) as "the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients." Today it should be the basis for all decisions made about the treatment of our patients. The experience of the clinician, values of the patient and best available scientific information should be integrated when decisions about clinical management are made. As scientists, veterinarians should always look at the available research evidence and advise clients accordingly. Whenever I think of the opposite of this, the many stories on the treatment of horses for African horse sickness I heard when I was involved with endurance riding come to mind – the most bizarre one being intravenous injections of formaldehyde. I always prayed that this approach was never followed by colleagues, as the evidence about this approach is mostly from pathologists who saw the damage that formaldehyde did to the poor animal’s blood vessels. It seems that, when desperation sets in, science moves out. This was the case with the above treatment of horses, and might well be the case with the hot topic of the day – treating people who suffer from COVID-19 with ivermectin. The jury is still out on this – most scientists agree that there is insufficient evidence to prove that ivermectin is a suitable treatment. With more and better evidence becoming available, we might find that it indeed is good treatment – or not. Perhaps there will also be trials to determine the side-effects with long- term use of ivermectin – keeping in mind that the drug is used as single, once-off treatment for most parasitic conditions (only repeated weeks or months later). You might say that extreme problems call for extreme measures. Or that veterinarians use drugs for off-label use almost daily. But we do so based on evidence, and not on the spur of the moment. On ivermectin, we need more evidence before it can be used as a general treatment for cases of COVID-19. And we should be very careful before selling the drug to people who come to our practices looking for it. Until next month! v Regards, From the Editor Reflections from a DamWall Paul van Dam

RkJQdWJsaXNoZXIy OTc5MDU=